107
Views
15
CrossRef citations to date
0
Altmetric
Drug Profile

Role of carvedilol controlled-release in cardiovascular disease

Pages 483-498 | Published online: 10 Jan 2014
 

Abstract

Carvedilol is a β1- and β2-adrenergic receptor antagonist with additional vasodilatory α1-blocking properties. Carvedilol was shown to be more efficacious than a traditional β-blocker for treating heart failure and improving myocardial function. Carvedilol is the only agent in its class to have been demonstrated to significantly reduce mortality and morbidity in post-myocardial-infarction patients with left ventricular dysfunction. Moreover, carvedilol does not exhibit the carbohydrate and lipid disturbances observed with other β-blockers. Originally available as a twice-daily formulation, a controlled-release, once-daily formulation of carvedilol is now available, which has equivalent efficacy and safety, as demonstrated by numerous studies. The convenience of once-daily dosing is expected to contribute to patient adherence, thereby potentially improving long-term clinical outcomes.

Financial & competing interests disclosure

The author has acted as a researcher and consultant, and has received honorarium from GlaxoSmithKline, Novartis, Pfizer and Medtronic. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Writing assistance was utilized in the production of this manuscript. The author would like to thank John O’Flaherty, PhD, ProEd Communications, Inc.®, for his medical editorial assistance with this manuscript. John O’Flaherty’s work was supported by GlaxoSmithKline, PA, USA.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.